The Center for Biosimilars® recaps the top news for the week of March 4, 2019.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of March 4.
Number 5: The FDA has approved a subcutaneously administered version of the brand-name trastuzumab, Herceptin.
Number 4: Mylan revealed in its recent earnings call that it had an initial advisory meeting with the FDA regarding a proposed biosimilar referencing the brand-name Botox.
Number 3: During the European Crohn’s and Colitis Organisation’s14th Congress, held in Copenhagen, Denmark, researchers presented on real-world switches from reference infliximab to biosimilar CT-P13.
Number 2: Eli Lilly and Company is introducing a lower-priced authorized generic of its insulin lispro injection in the United States.
Number 1: FDA Commissioner Scott Gottlieb, MD, will be stepping down from his post in 1 month.
Finally, last week, our e-newsletter asked how important you think employers are to the US biosimilars market.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.